Results 211 to 220 of about 28,228 (226)
Some of the next articles are maybe not open access.
Journal of Hypertension, 2000
Losartan is an angiotensin II receptor blocker indicated for treatment of hypertension. It also inhibits platelet agreggation through blockade of thromboxane A2/ prostaglandin H2 receptors, and has a uricosuric effect We determined the effect on ambulatory blood pressure (ABP) of 100 mg losartan monotherapy (L100) versus 50 mg losartan/12.5 mg ...
Patrick Owens +5 more
openaire +3 more sources
Losartan is an angiotensin II receptor blocker indicated for treatment of hypertension. It also inhibits platelet agreggation through blockade of thromboxane A2/ prostaglandin H2 receptors, and has a uricosuric effect We determined the effect on ambulatory blood pressure (ABP) of 100 mg losartan monotherapy (L100) versus 50 mg losartan/12.5 mg ...
Patrick Owens +5 more
openaire +3 more sources
JAMA: The Journal of the American Medical Association, 1995
To the Editor. —Losartan potassium (Cozaar, Merck & Co, Inc, West Point, Pa), the first angiotensin II receptor antagonist, has had labeling approved as an oral treatment for hypertension by the US Food and Drug Administration. It has been marketed by the manufacturer since April 1995.
openaire +2 more sources
To the Editor. —Losartan potassium (Cozaar, Merck & Co, Inc, West Point, Pa), the first angiotensin II receptor antagonist, has had labeling approved as an oral treatment for hypertension by the US Food and Drug Administration. It has been marketed by the manufacturer since April 1995.
openaire +2 more sources
How the antihypertensive losartan was discovered
Expert Opinion on Drug Discovery, 2006Based on interviews and publications, this case study is a history of how DuPont scientists discovered losartan, the first angiotensin II receptor antagonist. Essential aspects of the story include: i) the discovery occurred at a young and inexperienced pharmaceutical business; ii) three bench scientists had recently graduated from PhD programmes and ...
openaire +3 more sources
Losartan in patients with renal insufficiency.
The Canadian journal of cardiology, 1995A choice of many antihypertensive strategies is now offered for the treatment of the hypertensive patient with renal insufficiency. Angiotensin-converting enzyme (ACE) inhibitors appear to be the drugs of choice since they not only lower blood pressure but also reduce some important risk factors that may cause progressive loss of renal function, such ...
De Zeeuw, D. +2 more
openaire +2 more sources
Clinical safety and tolerability of losartan
Clinical Therapeutics, 1997Losartan is a novel orally active nonpeptidal antihypertensive agent that specifically blocks the angiotensin II type 1 receptor. This paper compares the short- and long-term safety and tolerability of losartan with those of placebo. Approximately 3800 patients with mild-to-severe essential hypertension were enrolled in 16 double-masked and 4 open ...
openaire +3 more sources
Journal of Human Hypertension, 2002 Losartan in post-transplant erythrocytosis
Nephrology Dialysis Transplantation, 1996D. C. Brennan +3 more
openaire +3 more sources